Description of theme 1
Description of theme 2
Description of theme 3
   
 

P.O. Box 9101
6500 HB, Nijmegen
Geert Grooteplein zuid 8
6525 GA, Nijmegen
The Netherlands
T +31 24 3610401
F +31 24 3610373

Bert van der Reijden is Associate professor at the Laboratory of Hematology, Department of Laboratory Medicine. He is member of the editorial board of Leukemia.
Dr. Bert A. van der Reijden

Leukemia and lymphoma are caused by acquired genetic mutations. Recent advances in the understanding of the biological processes that contribute to these diseases has resulted in the development of targeted therapies. These new forms of treatment specifically correct the (downstream) effects of mutations that contribute to malignant transformation. We perform research on altered biological pathways in leukemia development. Transcriptional regulation and protein ubiquitination are studied in depth because changes in these processes have been shown to be causal to disease development. Besides, we screen for new mutations that play a role in leukemia and lymphoma development. New molecular tests are being designed to improve disease classification, to detect mutations that have an important impact on the prognosis of individual patients and to accurately monitor the disease in time.

 
Recent key publications

Van Oers MHJ, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E,  Vranovsky A, Holte H, Hagenbeek A and Van der Reijden BA: BCL-2/IgH PCR status at the end of induction treatment is not predictive for progression free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol, 2010, in press.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA and Jansen JH: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet, 2009 41:838-42.

Marteijn JAF, van der Meer LT, Smit JJ, Noordermeer SM, Wissink W, Jansen P, Swarts HG, Hibbert RG, de Witte T, Sixma TK, Jansen JH, van der Reijden BA: The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains. Leukemia, 2009. 23:1480-9.

Marteijn JAF, Van der Meer LT, Van Emst L, Wissink W, De Witte T, Jansen JH and Van der Reijden BA: Gfi1 ubiquitination and proteasomal degradation is inhibited by the ubiquitin ligase Triad1. Blood, 2007. 110:3128-35.

Marteijn JAF, Van der Meer L, Van Emst L, Jansen P, De Witte Th, Jansen JH and Van der Reijden BA: Diminished proteasomal degradation results in accumulation of Gfi1 protein in monocytes. Blood, 2007. 109:100-108.

More publications